1. BERAC April 2004 Radiopharmaceutical Sub- committee Report

2. Charge from Director Office of Science “( in view of major recent opportunities) to reassess how BER support might best stimulate directions in radiopharmaceutical research that are most likely to find translation into routine medical practice.” Driven by concern for shortages –Key personnel, now and future –Optimized facilities and infrastructure

3. DOE BER Largely responsible for modern nuclear medicine – 99m Tc for cardiac, bone scanning, etc. –Many new probes and radiotracers for diagnosis and therapy –Patient care studies in the millions US and throughout the world Era of Molecular Imaging: Key molecules, sub- cellular proteinomics, gene expression, whole cell function

4. Imaging the process of stem cell repopulation of the bone marrow Gene expression labeling at 8 days

5. Imaging Anatomy and Function PROSTATE CANCER MRI MRSI 18 FDG PET-CT MRI T2 BOLD

6. Why DOE Essential infrastructure : physical sciences and expertise –Cyclotrons/ radiochemistry facilities –Radiochemistry, Organic Synthetic Chemistry Expertise, and biology relevant to modern imaging –Translates into unique facilities for molecular imaging tool development Correlative Programs can provide depth of scientific expertise –Structural Biology –Nanotechnology –GTL

7. Recommendations of RDP Sub- committee Centers of Excellence Training of Radiochemists and other chemists in allied disciplines, such as structural biology, medicinal chemistry Collaboration and joint planning with NIH and other key governmental agencies Regulatory review with FDA to faciitate probe development

8. Progress Partnership with NIH –Agreement on common goals BERAC RDP Recc.s and NIH Road map –Collaboration Role definition: DOE physical chemical and biologic science; NIH translatIon into man NIBIB, exploring joint programs with respect to nuclear medicine centers of excellence for technology development and training

9. Next Phase Detailed definition of “Centers of Excellence” and Training programs